May 19th, 2012
SciClone Reports Financial Results for the First Quarter 2012
FOSTER CITY, CA, May 09, 2012 (MARKETWIRE via COMTEX) –
SciClone Pharmaceuticals, Inc.
/quotes/zigman/77751/quotes/nls/scln SCLN
+0.52%
today reported
financial results for the first quarter ended March 31, 2012.
Revenues increased by 81% for the quarter ended March 31, 2012, to
$39.2 million, compared to revenues for the same period in the prior
year of $21.7 million. The increases in revenues in the first quarter
were due to the continued growth of the ZADAXIN business in China and
the inclusion of the NovaMed Pharmaceuticals, Inc. (NovaMed) revenues
since the date of the acquisition on April 18, 2011. For the first
quarter ending March 31, 2012, ZADAXIN revenues increased 37% to
$29.8 million compared to revenues for the same period in the prior
year of $21.7 million, and revenues attributable to the primary care
and oncology product lines were $9.4 million.
On a pro forma basis, assuming NovaMed had been acquired on January
1, 2011, revenues for the quarter ended March 31, 2012 would have
been $39.2 million compared to $28.2 million for the same period in
the prior year, an increase of $11.0 million.
“We are pleased to report that SciClone delivered a strong first
quarter 2012 performance with 37% ZADAXIN revenue growth year over
year, clearly growing ahead of the market. All our key products,
ZADAXIN, Depakine(R) and Aggrastat(R), contributed to this excellent
start for 2012,” said Friedhelm Blobel, Ph.D., SciClone President and
Chief Executive Officer. “We recently marked the one-year anniversary
of the SciClone-NovaMed acquisition, which was an occasion to
celebrate the significant accomplishments we’ve made integrating our
two companies. Our sales and marketing focused China team, which now
includes approximately 850 professionals, has greatly enhanced our
ability to expand commercial efforts more deeply and widely
throughout the China market, resulting in the increasing market
uptake of our expanded product portfolio. We believe we have created
a broad foundation for continuing to deliver strong financial results
in 2012 and further solidifying our position within the top tier of
specialty pharmaceutical companies in China.”
On a GAAP basis, SciClone’s net income for the first quarter of 2012
was $8.7 million, compared with $3.8 million for the same period in
the prior year, or $0.15 per share on both a basic and diluted basis
for the three months ended March 31, 2012, compared with $0.08 per
share on both a basic and diluted basis for the same period in the
prior year.
SciClone’s non-GAAP net income for the first quarter of 2012 was $9.6
million, compared with non-GAAP income of $4.9 million for the same
period in the prior year, or $0.17 and $0.16 per share on a basic and
diluted basis, respectively, for the three months ended March 31,
2012, compared with $0.10 per share on both a basic and diluted basis
for the same period in the prior year. Basic and diluted earnings per
share for the 2012 period reflect the issuance of 8.3 million shares
of common stock as part of the acquisition of NovaMed in April 2011.
SciClone believes this non-GAAP information is useful for investors,
taken in conjunction with SciClone’s GAAP financial statements,
because management uses such information internally for its
operating, budgeting and financial planning purposes. Non-GAAP
information is not prepared under a comprehensive set of accounting
rules and should only be used to supplement an understanding of
SciClone’s operating results as reported under GAAP. The non-GAAP
calculations and reconciliation to comparable GAAP measures were
derived principally as a result of the NovaMed acquisition and are
provided in the accompanying table titled “Reconciliation of GAAP to
Non-GAAP Net Income.”
Research and development (R&D) expenses for the first quarter of 2012
totaled $3.4 million, compared with $3.1 million for the same period
in the prior year. Following the Company’s announcement on March 2,
2012 regarding the futility of our SCV-07 clinical development
program in oral mucositis, the Company has taken certain steps to
reduce its future US-based clinical development expenses this year
and expects further substantial decreases in R&D expenses in 2013.
The increase in R&D for the quarter was primarily related to
severance costs associated with the discontinuation of the Company’s
SCV-07 program, and to a lesser extent to the addition of NovaMed’s
research and development expenses since its acquisition in April
2011, offset partially by a decrease in third-party expenses related
to the discontinuance of our US-based clinical development programs.
Sales and marketing expenses for the first quarter of 2012 were $17.6
million, compared with $5.2 million for the same period in the prior
year. The increase of $12.4 million was primarily a result of the
addition of approximately 450 sales and marketing employees through
the acquisition of NovaMed in April 2011, as well as the additional
expansion of the Company’s sales team by approximately 100 sales
representatives in the fourth quarter of last year, which
significantly expanded SciClone’s sales and marketing capabilities.
The Company now has a combined sales organization comprised of
approximately 850 sales and marketing focused professionals in China.
General and administrative expenses for the first quarter of 2012
were $4.0 million, compared with $6.0 million for the same period in
the prior year. The decrease in 2012 was primarily due to lower
professional services fees related to the Company’s FCPA
investigation, class action and derivative lawsuits, and professional
expenses in connection with the NovaMed acquisition, partially offset
by increases in general and administrative expenses attributable to
NovaMed operations.
At March 31, 2012, cash and investments totaled $74.9 million,
compared with $67.0 million at December 31, 2011. The increase in
SciClone’s cash balance was primarily due to the cash generated by
the Company’s commercial operations, partially offset by $1.1 million
used in the first quarter for the repurchase of SciClone stock.
Conference Call Today
SciClone is hosting a conference call today at 4:30 pm ET to provide
a financial update. The call will be hosted by Friedhelm Blobel,
Ph.D., President and CEO, Gary Titus, Senior Vice President and CFO.
LIVE CALL:
866 730.5768 (U.S./Canada)
857 350.1592 (International)
Passcode: 27284305
REPLAY:
888 286.8010 (U.S./Canada)
617 801.6888
(International)
Passcode: 13769826
(Replay available from Wednesday,
May 9, 2012, at 6:30 pm ET until 11:59 pm ET on Wednesday, May 16,
2012)
The conference call will contain forward-looking statements.
Interested parties who wish to listen to the webcast should visit the
Investor Relations section of SciClone’s website at
www.sciclone.com .
The information provided on the teleconference is accurate only at
the time of the conference call, and SciClone will take no
responsibility for providing updated information except as required
by law.
About SciClone
SciClone Pharmaceuticals is a revenue-generating, profitable,
specialty pharmaceutical company with a substantial commercial
business in China and a product portfolio of therapies for oncology,
infectious diseases and cardiovascular, urological, respiratory, and
central nervous system disorders. SciClone’s ZADAXIN(R) (thymalfasin)
is approved in over 30 countries and may be used for the treatment of
hepatitis B (HBV), hepatitis C (HCV), and certain cancers, and as a
vaccine adjuvant, according to the local regulatory approvals.
Besides ZADAXIN, SciClone markets about 15 mostly partnered products
in China, including Depakine(R), the most widely prescribed
broad-spectrum anti-convulsant in China; Tritace(R), an ACE inhibitor
for the treatment of hypertension; Stilnox(R), a fast-acting hypnotic
for the short-term treatment of insomnia (marketed as Ambien(R) in
the US); and Aggrastat(R), a recently-launched interventional
cardiology product. SciClone is also pursuing the registration of
several other therapeutic products in China. SciClone is
headquartered in Foster City, California. For additional information,
please visit
www.sciclone.com .
Forward-Looking Statements
This press release contains forward-looking statements regarding
expected financial results and expectations. Readers are urged to
consider statements that include the words “may,” “will,” “would,”
“could,” “should,” “might,” “believes,” “estimates,” “projects,”
“potential,” “expects,” “plans,” “anticipates,” “intends,”
“continues,” “forecast,” “designed,” “goal,” “unaudited,”
“approximately” or the negative of those words or other comparable
words to be uncertain and forward-looking. These statements are
subject to risks and uncertainties that are difficult to predict and
actual outcomes may differ materially. These include risk and
uncertainties relating to: the course, cost and outcome of regulatory
matters, including pricing decisions by authorities in China; the
on-going regulatory investigations; the Company’s ability to execute
on its goals in China and on its objectives for revenue in fiscal
2012; the challenges presented by integrating an acquired business
into existing operations; the variability in earnings on a GAAP basis
that may result from non-cash charges related to the NovaMed
acquisition; the dependence on third party license, promotion or
distribution agreements including the need to renew such agreements;
operating an international business; the clinical trial process,
including the regulatory approval and the process of initiating
trials at, and enrolling patients at, clinical sites; the effect of
changes in its practices and policies related to the Company’s
compliance programs. SciClone cannot predict the timing or outcome of
the SEC and DOJ investigations, or of the level of its efforts
required to cooperate with those investigations, however the Company
has incurred substantial expenses in connection with the
investigations and related litigation and expects to incur additional
expense and the investigations could result in fines and further
changes in its internal control or other remediation measures that
could adversely affect its business. Please also refer to other risks
and uncertainties described in SciClone’s filings with the SEC. All
forward-looking statements are based on information currently
available to SciClone and SciClone assumes no obligation to update
any such forward-looking statements.
Ambien, Depakine, Stilnox and Tritace are registered trademarks of
Sanofi and/or its affiliates.
Aggrastat is a registered trademark of Medicure International Inc. in
the United States, and Iroko Cardio LLC in numerous other countries.
SciClone, SciClone Pharmaceuticals, the SciClone Pharmaceuticals
design, the SciClone logo and ZADAXIN are registered trademarks of
SciClone Pharmaceuticals, Inc. in the United States and numerous
other countries.
UNAUDITED CONSOLIDATED STATEMENTS OF OPERATIONS
(in thousands, except per share amounts)
Three Months Ended
March 31,
————————
2012 2011
———– ———–
Net revenues:
Product sales $ 31,258 $ 21,662
Promotion services 7,905 –
———– ———–
Total revenues, net 39,163 21,662
Operating expenses:
Cost of product sales 4,941 3,103
Sales and marketing 17,640 5,228
Amortization of acquired intangible assets,
related to sales and marketing 884 –
Research and development 3,393 3,109
General and administrative 3,961 5,958
Contingent consideration* (916) –
———– ———–
Total operating expenses 29,903 17,398
———– ———–
Income from operations 9,260 4,264
Non-operating income (expense):
Interest income 30 20
Interest expense (55) (57)
Other (expense) income, net (1) 15
———– ———–
Income before provision for income tax 9,234 4,242
Provision for income tax 554 393
———– ———–
Net income $ 8,680 $ 3,849
=========== ===========
Basic net income per share $ 0.15 $ 0.08
Diluted net income per share $ 0.15 $ 0.08
Weighted average shares used in computing:
Basic net income per share 57,701 48,020
Diluted net income per share 59,691 50,402
UNAUDITED SELECTED BALANCE SHEET DATA
(in thousands)
March 31, December 31,
2012 2011
————- ————-
Cash and investments $ 74,855 $ 67,018
Accounts receivable 42,056 42,226
Inventories 8,518 8,813
Intangible assets, net 44,428 45,185
Goodwill 32,074 31,973
Total assets 206,997 200,326
Total current liabilities 24,114 25,284
Contingent consideration 14,484 15,400
Deferred tax liabilities 8,351 8,715
Borrowing on line of credit 2,500 2,500
Total shareholders’ equity 159,649 150,458
RECONCILIATION OF GAAP TO NON-GAAP NET INCOME
(in thousands, except per share amounts)
(unaudited)
Three Months Ended
March 31,
—————————-
2012 2011
————- ————-
GAAP net income $ 8,680 $ 3,849
Non-GAAP adjustments:
Employee stock-based compensation 922 525
Contingent consideration (916) –
Amortization of acquired intangible assets 884 –
Acquisition related costs — 562
————- ————-
Non-GAAP net income $ 9,570 $ 4,936
============= =============
Non-GAAP basic net income per share $ 0.17 $ 0.10
Non-GAAP diluted net income per share $ 0.16 $ 0.10
Weighted average shares used in computing:
GAAP and Non-GAAP basic net income per share 57,701 48,020
GAAP and Non-GAAP diluted net income per share 59,691 50,402
SciClone management uses these non-GAAP financial measures to monitor
and evaluate the Company's operating results and trends on an
on-going basis and internally for operations, budgeting and financial
planning purposes. SciClone believes the non-GAAP information is
useful for investors by offering them the ability to better
understand how management evaluates the business. These non-GAAP
measures have limitations, however, because they do not include all
items of income and expenses that affect SciClone. These non-GAAP
financial measures that management uses are not prepared in
accordance with, and should not be considered in isolation of, or as
an alternative to, measurements required by GAAP.
SciClone's non-GAAP financial measures exclude the following items
from GAAP net income and net income per share:
-- Employee stock-based compensation. The effects of non-cash employee
stock-based compensation.
-- *Contingentconsideration. The contingent consideration related to the
acquisition of NovaMed is re-measured each reporting period and the
change in fair value is recorded as an adjustment to operating
expense. SciClone's non-GAAP financial measure excludes the change in
fair value of the liability for contingent consideration in connection
with the acquisition of NovaMed.
-- Amortization of acquired intangible assets. We recorded intangible
assets in connection with the acquisition of NovaMed. The amortization
of these intangible assets is excluded from SciClone's non-GAAP
financial measure.
-- Acquisition related costs. We incurred certain one-time acquisition
costs related to the acquisition of NovaMed. The effects of these
acquisition related costs are excluded from SciClone's non-GAAP
financial measure.
Corporate Contacts
Gary Titus
Chief Financial Officer
650.358.3456
gtitus@sciclone.com
Jane Green
Investors/Media
650.358.1447
jgreen@sciclone.com
SOURCE: SciClone Pharmaceuticals, Inc.
mailto:gtitus@sciclone.com
mailto:jgreen@sciclone.com
Copyright 2012 Marketwire, Inc., All rights reserved.
/quotes/zigman/77751/quotes/nls/scln
Add to portfolio
SCLN
SciClone Pharmaceuticals Inc.
US
: U.S.: Nasdaq
$
5.80
+0.03
+0.52%
Volume: 507,314
May 18, 2012 4:00p
P/E Ratio10.40
Dividend YieldN/A
Market Cap$327.71 million
Rev. per Employee$172,734
Financial Glossary
Words used in this article: